Table 2.
The association between FPGS rs1544105 genotypes and patient characteristics (N = 164)
| Characteristics |
FPGS
SNP rs1544105 |
p -value* | |
|---|---|---|---|
|
CC |
CT + TT |
||
| genotype | genotype | ||
| Gender |
|
|
1.000 |
| Male |
9 (62.3) |
95 (63.3) |
|
| Female |
5 (35.7) |
55 (36.7) |
|
| Age (years) |
|
|
0.336 |
| <1 |
0 |
0 |
|
| 1-9 |
13 (92.9) |
123 (82.0) |
|
| ≥10 |
1 (7.1) |
27 (18.0) |
|
| Treatment group |
|
|
0.797 |
| SR |
4 (28.6) |
58 (38.7) |
|
| MR |
8 (57.1) |
73 (48.7) |
|
| HR |
2 (1.3) |
19 (12.6) |
|
| WBC (109/L) |
|
|
0.710 |
| <50 |
11 (78.6) |
125 (83.3) |
|
| ≥50 |
3 (21.4) |
25 (16.7) |
|
|
TEL-AML1 |
|
|
0.770 |
| Positive |
3 (21.4) |
38 (25.3) |
|
| Negative |
11 (78.6) |
112 (74.7) |
|
|
E2A-PBX1 |
|
|
1.000 |
| Positive |
1 (7.1) |
15 (10.0) |
|
| Negative |
13 (92.9) |
135 (90.0) |
|
|
BCR-ABL |
|
|
0.141 |
| Positive |
2 (14.3) |
6 (4.0) |
|
| Negative |
12 (85.7) |
144 (96.0) |
|
|
MLL-AF4 |
|
|
1.000 |
| Positive |
0 |
1 (0.6) |
|
| Negative |
14 (100.0) |
149 (99.4) |
|
| Prednisone response |
|
|
0.164 |
| Good |
1 (7.1) |
1 (0.6) |
|
| Poor |
13 (92.9) |
149 (99.4) |
|
| CNS involvement |
|
|
1.000 |
| Absent |
14 (100.0) |
148 (98.7) |
|
| Present | 0 | 2 (1.3) | |
*Data were calculated by χ2 test. WBC, white blood cell count; SR, standard-risk; MR, medium-risk; HR, high-risk; CNS, central nervous system.